Diet and Behavior in Dogs: Mechanisms, Trials and What Holds Up

1. The Tryptophan Pathway

1.1 The Mechanism

Tryptophan is the precursor of serotonin and an essential amino acid, meaning it must come from food. Crossing into the brain requires a shared transporter, and tryptophan competes for it with other large neutral amino acids.

The consequence is counterintuitive and correct: a protein-rich meal delivers more tryptophan but also more competitors, so raising dietary protein can lower the amount reaching the brain. Carbohydrate shifts the ratio favorably through insulin-mediated uptake of competing amino acids into muscle.

1.2 Why the Logic Is Attractive

Serotonergic function is associated with anxiety-related behavior, and the pathway offers something rare — an intervention an owner can implement without training, medication or a professional (unlike anxiety treatment generally).

1.3 The Gap Between Mechanism and Effect

The standard overview of the field set out these mechanisms alongside their limits, describing them as possible rather than demonstrated (Bosch, Beerda, Hendriks, van der Poel & Verstegen, 2007). That framing is worth carrying forward, because everything above is about substrate availability. None of it demonstrates that the resulting change in brain serotonin is large enough, or sustained enough, to alter behavior. That is an empirical question, and it has been tested.

2. What the Trials Found

2.1 The Study Everyone Cites

DeNapoli et al. (2000) fed 33 dogs four rations for one week each, testing protein content and tryptophan supplementation against territorial aggression, "dominance aggression" and hyperactivity.

Within each behavioral group, no effect reached significance. Only in the pooled analysis did territorial aggression scores come out lower with high tryptophan — and only when protein was simultaneously low (DeNapoli et al., 2000).

2.2 What That Study Cannot Support

One week per ration, 33 dogs, a within-group null result, and a pooled finding conditional on two variables at once. It is a reasonable pilot and it is the source of nearly every "feed less protein for aggression" recommendation in circulation.

The terminology is also dated. "Dominance aggression" reflected the standard of 2000 and is no longer a defensible category (as the dominance evidence sets out) — the study is cited here with its original terms without adopting the construct.

2.3 The Strongest Controlled Trial Found No Effect

For eight weeks, privately owned dogs received either a control diet (n = 66) or a diet containing 2.6-fold more tryptophan (n = 72), randomised, double-blinded and placebo-controlled. Assessment combined a controlled open-field test with the C-BARQ questionnaire (Bosch et al., 2009).

Dietary tryptophan had no significant effect on anxious behavior.

The strongest controlled trial currently available on this question. It used a substantial supplementation dose over a realistic period, and it returned a null result. Despite its methodological strength, it receives less attention in commercial communication than earlier positive interpretations.

2.4 The Remaining Trials

Templeman et al. (2018) gave graded tryptophan concentrations to 36 adult female hound-cross dogs and measured behavior on approach by familiar and unfamiliar people. Effects were small.

That study requires a disclosure: two authors were previously employed by Procter & Gamble Pet Care and declare financial and personal interests in the company. It is reported here with that caveat rather than excluded.

The subject population also limits generalization — 36 healthy adult females from a single hound-cross line, tested on approach behavior rather than on a clinical problem. Whether the same doses would move anything in a dog presented for anxiety is untested.

3. The Caregiver Placebo Effect

3.1 The Problem With Owner-Reported Outcomes

Almost every claim about diet and behavior rests on someone's judgment that the dog seems calmer. Behavior has no equivalent of a blood value, so the outcome measure in most of this literature is a person's impression — and that impression has been measured against an objective standard in dogs.

The measurement was made in orthopedics rather than behavior, because orthopedics has an objective comparator that behavior lacks (as the judgement-bias work handles the same measurement problem).

3.2 What Was Found

Fifty-eight dogs with lameness from osteoarthritis were followed in the placebo arm of a randomized, double-blinded, placebo-controlled multicenter trial, with owner and veterinarian assessments compared against force platform gait analysis (Conzemius & Evans, 2012).

A caregiver placebo effect occurred 39.7% of the time when owners evaluated their dog's lameness, and between 43.1% and 44.8% of the time when veterinarians assessed lameness at a walk, at a trot, or pain on palpation. The effect grew significantly with time. Meanwhile, of the 58 dogs, 46 showed ground reaction forces that were unchanged over 42 days (Conzemius & Evans, 2012).

3.3 The Same Pattern With a Different Outcome

Seizure frequency is countable, which makes it a useful second test. A meta-analysis of the three then-known prospective placebo-controlled canine epilepsy trials found that 22 of 28 dogs receiving placebo showed a decrease in seizure frequency relative to baseline, and 8 of them — 29% — would have counted as responders under a 50% reduction criterion (Muñana, Zhang & Patterson, 2010).

Average reductions during placebo across the three trials were 26%, 29% and 46%. An uncontrolled study of any intervention in dogs with epilepsy would therefore be expected to report a substantial success rate before the intervention does anything.

3.4 The Complication in Dietary Trials Specifically

The picture is not simply that placebo response is always large. Re-analysis of six months of seizure data from 60 dogs with idiopathic epilepsy across three dietary trials, all prospective randomized double-blinded placebo-controlled crossover designs, found no placebo response in monthly seizure frequency at all. Frequency instead rose during placebo, from a mean of 2.30 to 2.95 seizures per month (Schmidt et al., 2024).

A phase effect appeared as well: dogs receiving placebo in the second half of the study showed a significant increase relative to baseline, while those receiving it in the first half did not. The authors conclude that placebo responses in canine epilepsy trials vary considerably, contrasting with the earlier limited data (Schmidt et al., 2024).

3.5 What This Means for Reading Diet Claims

The lesson is not that owners are unreliable witnesses. It is that owner impressions can move substantially while the underlying variable does not, that the direction and size of that movement depend on trial design, and that no dietary claim resting on unblinded owner report can be distinguished from this.

Behavior has no force platform. That absence is the single most consequential methodological fact in this field, and it applies equally to a manufacturer's trial and to an owner's own two-week experiment at home (where transfer across contexts turns out not to be automatic).

4. What a Diet-Behavior Trial Has to Control

4.1 Blinding That Actually Holds

Diets differ in smell, texture, color and how eagerly a dog approaches the bowl. An owner who is meant to be blinded but can see their dog attacking one food and picking at the other is not blinded, and the outcome measure is that owner's judgment.

This is harder in nutrition than in pharmacology, where an identical capsule solves the problem, and it is rarely addressed explicitly in the reporting.

4.2 Crossover and Washout

Crossover designs let each dog serve as its own control, which matters when individual variation is large relative to the effect being sought (with individual variation doing more work than usually assumed). They introduce their own requirement: enough washout between conditions that the first diet is no longer acting.

How long that takes for a hypothesized behavioral effect is not established, because nobody knows the time course of the effect they are looking for.

4.3 Order and Phase Effects

The dietary epilepsy re-analysis found that when in the study a dog received placebo changed the result (Schmidt et al., 2024). That is a warning about crossover designs generally: the same condition can produce different numbers depending on where it sits in the sequence.

Randomizing order handles this only if the sample is large enough for randomization to balance it, which in this literature it often is not.

4.4 What Else Changed With the Diet

A diet change is rarely one variable. Caloric density, meal volume, feeding frequency, palatability and how much attention the owner is now paying to the dog all move together, and several of them plausibly affect behavior on their own.

A trial that finds an effect has to argue that the nominated nutrient produced it rather than any of the accompanying changes, and few in this area are designed to make that argument (as the noise literature shows for a different outcome).

4.5 Outcome Measures That Could Be Wrong

The strongest available fix is an outcome that does not depend on impression: coded video scored by a blinded observer, latency or frequency counts of a defined behavior, or a standardized test with a predefined scoring protocol.

These are more expensive than a questionnaire and they are the difference between a result and a report. Where a study uses them and finds nothing, that null result is considerably more informative than a positive finding from owner ratings.

5. Correlation Without Intervention

5.1 The Metabolomic Finding

Non-targeted metabolite profiling found that fearful dogs differed from non-fearful dogs in several pathways, including tryptophan metabolism and oxidative stress markers (Puurunen et al., 2016).

5.2 How It Is Usually Read

As confirmation that tryptophan drives fearfulness. It is not. The design is cross-sectional and observational: it establishes that fearful dogs have a different metabolic profile, not that the profile caused the fear or that changing it would help.

Chronic stress alters metabolism, which makes reverse causation at least as plausible (with the physiological consequences documented).

5.3 The Measurement Caveat

Serum and plasma concentrations are not brain concentrations. The blood–brain barrier is the entire point of the mechanism described in section 1, and any inference from a circulating value to central serotonergic function has to cross it (a limitation that applies to canine neurochemistry generally).

6. The Microbiome

6.1 Why It Displaced Tryptophan

Gut microbes influence host physiology through neural, immune and endocrine routes, and the framing is genuinely interesting (set out separately in the gut–brain literature). It has also become the new home for the same confident claims that tryptophan supported a decade ago.

One difference should be stated before going further, because it changes how the two literatures compare. The tryptophan question has been tested by intervention — dogs were given the substance and their behavior was measured against controls. The canine microbiome literature is almost entirely observational: groups are compared, correlations are reported, and no study has altered a dog's microbiome and then measured whether behavior changed. The evidence is not weaker in the same way; it is weaker in a different and more fundamental one.

6.2 The Early Studies

Kirchoff, Udell & Sharpton (2019) found gut microbiome composition to correlate with conspecific aggression in a small population of rescued dogs, with the authors noting the limitations themselves.

Mondo et al. (2020) compared 11 aggressive, 13 phobic and 18 unremarkable dogs. The reported differences concern microbiome composition — the adrenocortical measures showed no significant differences between the three groups, a detail that is frequently dropped when the study is summarized.

6.3 The Most Comprehensive Study

Pellowe et al. (2025) assigned pet dogs to higher or lower anxiety and aggression groups by C-BARQ and sequenced faecal samples. The result is worth stating precisely: minimal differences in relative abundance were seen between behavioral groups, and it was machine-learning and compositional balance models that could predict group membership from microbiota composition.

That is pattern detection, not a demonstrated causal pathway.

6.4 The Field's Own Assessment

A critical review by Crisante and colleagues, including Mills, concluded that the gut microbiome may influence dog behavior but that specific findings are not definitive, that the evidence linking canine gut microbiota to anxiety, aggression and cognition is preliminary, and that standardized methodologies are needed to improve comparability and replicability (Crisante et al., 2025).

When the researchers working in a field describe their own evidence base as preliminary, that assessment should outrank product marketing.

6.5 Composition Is Not Function

All three canine studies above report composition — which organisms are present and in what relative abundance. That is what sequencing a faecal sample returns, and it is the least expensive part of the question to measure.

What the mechanistic story requires is different: what those organisms produce. Metabolic output is the proposed route by which gut microbes could reach the nervous system, and it is measured separately from composition. Two dogs with different community profiles can produce comparable output, and two with similar profiles can differ in it.

6.6 The Barrier in Between

A second step sits between the community and the animal. Whatever is produced in the gut has to cross the intestinal barrier to reach circulation, and barrier integrity is a variable in its own right that none of the composition studies assessed.

Neither point is an objection to the hypothesis. They name two measurement steps standing between a composition difference and a behavioral effect, which is why "the microbiome differs between anxious and calm dogs" is several steps short of a mechanism (where transfer across contexts turns out not to be automatic).

7. Where Diet Genuinely Matters

7.1 Pain and Discomfort

The strongest link between what a dog eats and how it behaves runs through discomfort rather than through neurotransmitters. Pain has a substantial presence in behavior caseloads (Mills et al., 2020), and gastrointestinal discomfort is a route that is easy to overlook (as visceral pain illustrates).

A dog with recurrent abdominal pain may become irritable, restless or intolerant of handling. That is a real diet–behavior connection, and it has nothing to do with serotonin.

7.2 Adverse Food Reactions

Food allergy and intolerance produce dermatological and gastrointestinal signs, and both are sources of chronic low-grade discomfort. The behavioral consequence is indirect and can be substantial (with chronic pain having documented behavioral effects).

7.3 Feeding Structure

Predictability, distribution across the day, and a settled period after eating are unglamorous and more defensible than any nutrient manipulation. Structure reduces anticipatory arousal (which is what constrains learning), and a dog fed once daily at an unpredictable time has a different day from one fed on a schedule.

The settled period afterwards has its own justification. Rest following activity is associated with better consolidation of what was learned beforehand (as the sleep evidence indicates), which makes a post-meal quiet phase more than a digestive courtesy.

7.4 Hunger, Frustration and Impulse Control

A hungry dog is a different training subject. Food motivation rises, which raises reinforcer value — and also raises frustration when access is delayed or blocked (with frustration having a documented behavioral signature).

The practical consequence cuts both ways. Training a dog before its meal exploits genuine motivation; training a dog that is genuinely hungry and then working on impulse control sets it against a state that makes inhibition harder.

Reduced intake matters in the other direction. A dog eating poorly — from illness, stress or an unpalatable ration — has less to work with physically, and reduced resilience shows up as lower tolerance for handling and shorter working spans before quality drops.

7.5 Food as a Training Tool

The best-supported role of food in behavior is as a reinforcer. Reinforcer value is manageable, food searching is usable for arousal regulation, and scatter feeding provides enrichment (with reinforcement schedules affecting persistence).

Worth separating clearly: training food and the daily ration are different things, and treating them as one leads either to an overfed dog or to a trainer without currency (where the reinforcer is the mechanism).

8. What to Do With a Suspected Diet–Behavior Link

8.1 Document Before Changing

A feeding and behavior log over seven to fourteen days — what, when, how much, and what the dog did — turns an impression into data. Without timestamps there is no pattern, only recollection (and recollection is where interpretation slips in).

8.2 One Variable, Enough Time

Change one thing at a time and allow weeks rather than days. Simultaneous changes to food, routine and training make attribution impossible — and behavioral fluctuation is large enough that short observation windows produce spurious effects in both directions.

8.3 Medical Before Nutritional

New or changed behavior warrants veterinary assessment before dietary experimentation. A diet change that appears to help may be masking a condition that will re-emerge, and elimination diets are diagnostic procedures with rules rather than something to improvise.

8.4 Where the Boundary Sits

Structuring feeding, using food in training and documenting patterns fall within a behavior professional's scope. Diagnosing intolerance, formulating rations and recommending supplements do not (a boundary that also applies to pain assessment).

9. Who Funds This Research

9.1 Why the Question Is Not Rhetorical

Canine nutrition is an industry before it is a research field, and the studies that test whether food changes behavior are largely run by people with a professional relationship to food manufacturers. That is not a scandal — it is how applied nutrition research is funded in most species, including humans — but it is a variable a reader is entitled to know about.

The relevant question is never whether a funded study is dishonest. It is which questions get asked, which get published, and how a disclosed relationship travels when the finding is summarized elsewhere.

9.2 What the Tryptophan Study Discloses

The graded-tryptophan trial states its support directly: the work was supported by The Iams Company, Procter and Gamble — Pet Care Division. The author disclosure records that three authors report no conflicts of interest, while two had previously been employed by Procter and Gamble — Pet Care and had held financial and personal interest in the company (Templeman et al., 2018).

That is a properly made disclosure. The authors did what the system asks of them, and the study is not weakened by their having said so.

9.3 What Happens to the Disclosure Afterwards

What does not survive is the context. A disclosure printed at the end of a journal article does not travel into a product page, a training blog or a summary that cites the study for a single sentence.

By the time the finding reaches an owner, the funding relationship has been filtered out along with the sample size, the effect size and the conditions under which the result held (a pattern that recurs wherever a plausible mechanism outruns its trials).

9.4 Where the Evidence Piles Up

Observation is cheaper than intervention in every corner of this field. Comparing gut microbial composition between aggressive and non-aggressive dogs needs samples and sequencing; showing that changing the microbiome changes behavior needs a controlled trial with a blinded outcome measure and a time course nobody has established.

The literature therefore accumulates the first kind of study considerably faster than the second, and the imbalance says nothing about which kind answers the question (where transfer across contexts turns out not to be automatic).

9.5 Why Volume Gets Mistaken for Weight

When a field has many correlational studies and few trials, the number of citable papers can be read as strength of evidence. Counting publications is not the same as counting tests of the claim.

A reader who encounters a dozen microbiome papers cited in support of a dietary product has not encountered a dozen attempts to change behavior by changing what a dog eats. In most cases they have encountered none.

9.6 The Asymmetry Worth Naming

Industry funding shapes the literature less through individual studies than through which studies exist at all. Trials testing whether a supplement helps are commercially motivated; trials testing whether a widely sold supplement does nothing are not.

The result is a body of evidence weighted toward the questions someone had a reason to ask, which is a different problem from bias within any one paper and is not fixed by disclosure statements.

10. Reading a Diet Claim

10.1 Was Anything Compared?

The first question is whether the claim rests on a comparison at all. "Dogs on this food are calmer" is compatible with no comparison group, with a comparison against a different food, or with a comparison against the same dogs before the change — and those three support very different conclusions.

Before-and-after in the same dogs is the weakest of the three and the most common, because it is what an owner or a company can produce without a trial.

10.2 Who Judged the Outcome, and Did They Know?

The second question is who decided the dog improved and whether that person knew which condition the dog was in. Given how large caregiver placebo effects can be (Conzemius & Evans, 2012), an unblinded judgment is not evidence about the diet.

This applies symmetrically. An owner convinced a food made things worse is subject to the same effect in the other direction.

10.3 Is the Nutrient Doing the Work?

The third question is whether the named ingredient is the only thing that changed. Where a supplement is added to an existing diet, the answer can be yes. Where a whole food is swapped, several variables moved together and the claim about the nutrient is an interpretation rather than a result.

Marketing almost invariably attributes the change to the named ingredient, because that is the part being sold.

10.4 What Would Have Counted as a Failure?

The last question is the most useful and the least often answerable. If the claim had been wrong, what observation would have shown it? A claim that predicts calmness, or reduced reactivity, or better focus, without specifying how much or measured how, cannot fail.

The trials described earlier in this article did specify, which is why some of them returned nothing — and why those null findings are worth more than a page of testimonials (as the judgement-bias work handles the same measurement problem).

11. Why the Claims Persist

11.1 A Mechanism Is Not a Result

The tryptophan pathway is teachable, memorable and true as biochemistry. That makes it persuasive independently of whether the intervention works, and a plausible mechanism reliably outcompetes a null result in public communication.

11.2 Something Sellable

Diet is the one variable an owner controls completely, and unlike training it can be bought. Every element of the chain — protein level, tryptophan supplement, probiotic, "calming" formula — has a product attached (unlike the interventions that are actually supported).

11.3 It Displaces the Harder Work

A dietary change is a single decision. Behavior modification is weeks of graded exposure and consistent handling (with relapse built into the process). Where the two are presented as alternatives, the easier one wins — and the dog spends that time without the intervention that would have worked.

11.4 Null Results Do Not Travel

Bosch et al. (2009) is the strongest study in this area and among the least cited outside academic work. This is the standard asymmetry, and it is worth naming because it explains why the advice landscape looks the way it does (the same reporting bias affects other canine literatures).

11.5 Blinding Yourself, Roughly

An owner cannot run a double-blind trial at home, but the failure mode is known and partly avoidable. Deciding in advance what would count as improvement, writing it down before the change, and counting something specific rather than recalling a general impression removes the largest part of the problem.

Having someone who does not know a diet was changed comment on the dog after two weeks is cruder than a blinded observer and better than nothing.

11.6 Expect Regression to the Mean

Diet changes are usually made when things are bad, and things that are bad tend to get somewhat better on their own. A trial that starts at a peak will show improvement whatever is fed, which is one mechanism behind the placebo findings above and is not a criticism of anyone's observation.

Baseline recorded over several weeks before the change, rather than on the worst day, is the correction available to a private household.

11.7 When to Stop Testing Diets

Diet trials at home have a cost that is easy to overlook. Each one takes weeks, occupies the owner's attention, and postpones whatever else might be causing the behavior. A household on its fourth food in six months has spent half a year not addressing the problem.

Two failed, properly run attempts is a reasonable point to stop and look elsewhere — at pain, at the training history, at what the dog is being asked to cope with daily. That is not a counsel of despair. It is where the evidence in this article says the larger effects are.

11.8 What a Genuine Response Looks Like

An adverse food reaction that resolves on an elimination diet and returns on rechallenge is a real, repeatable result and belongs in a different category from a general impression of calmness. Rechallenge is what separates the two, and it is the step most often skipped because nobody wants to make a dog worse again.

Skipping it is understandable and it means the conclusion stays provisional.

12. Summary at a Glance

The mechanism is real — Tryptophan competes with other large neutral amino acids for brain entry, so higher dietary protein can reduce uptake.

The most-cited study is a small pilot — 33 dogs, one week per ration, no within-group effect; the pooled finding required high tryptophan and low protein simultaneously (DeNapoli et al., 2000).

The strongest controlled trial found no effect — Randomised, double-blinded, placebo-controlled, 66 versus 72 dogs, eight weeks, 2.6-fold tryptophan: no significant effect on anxious behavior (Bosch et al., 2009).

Graded dosing produced small effects — 36 hound-cross females, with two authors declaring prior employment and financial interests at a pet food company (Templeman et al., 2018).

Metabolomic differences are correlational — Fearful dogs differ in tryptophan metabolism, which does not establish direction (Puurunen et al., 2016).

Microbiome differences are minimal in the best study — Only machine-learning and compositional models could predict behavioral group; relative abundance differences were minimal (Pellowe et al., 2025).

The field calls its own evidence preliminary — Findings are not definitive and standardized methods are needed (Crisante et al., 2025).

Where diet does matter is discomfort — Pain and gastrointestinal upset affect behavior directly, without any serotonergic route (Mills et al., 2020).

Owner and veterinary judgment moves when nothing does — In the placebo arm of a controlled trial, a caregiver placebo effect appeared 39.7% of the time for owners and 43.1–44.8% for veterinarians, while 46 of 58 dogs showed unchanged ground reaction forces (Conzemius & Evans, 2012).

Placebo response appears with countable outcomes too — Across three canine epilepsy trials, 22 of 28 placebo-treated dogs showed reduced seizure frequency and 29% would have counted as responders (Muñana, Zhang & Patterson, 2010).

But it is not a constant — In three dietary epilepsy trials with crossover designs, no placebo response appeared; seizure frequency rose during placebo, and the result depended on study phase (Schmidt et al., 2024).

The tryptophan trial was industry-supported and said so — Funded by The Iams Company, Procter and Gamble — Pet Care Division, with two of five authors disclosing prior employment and financial interest there (Templeman et al., 2018).

13. Research Gaps and Critical Appraisal

Controlled trials are few. Among the available studies, Bosch et al. (2009) remains the strongest controlled trial — randomised, blinded and placebo-controlled with adequate numbers — and it found no significant effect. Nothing of comparable design has produced a positive result.

Trial durations are short. One week per ration in the most-cited study. Whether longer exposure would produce effects is untested, and the eight-week trial that did run found none.

Owner-reported outcomes dominate. C-BARQ is validated and measures owner perception, which in an unblinded context is exactly where expectancy effects operate. The blinding in Bosch et al. is part of why its null result carries weight.

Microbiome samples are small and cross-sectional. Eleven aggressive dogs in one study, a small rescue population in another. No canine study has tracked microbiome and behavior longitudinally, and none has demonstrated that altering the microbiome alters behavior.

Methodology is not standardized. Sequencing approaches, behavioral measures and sampling protocols differ enough that studies cannot be directly compared — the review's central criticism (Crisante et al., 2025).

Brain measurements do not exist. No canine study has measured central serotonin in relation to dietary manipulation. The entire mechanistic argument rests on inference from circulating concentrations across a barrier whose selectivity is the mechanism.

Conflicts of interest are common and unevenly declared. Pet food manufacturers fund a substantial share of nutrition research. Templeman et al. (2018) declare theirs; readers of secondary coverage rarely see such declarations at all.

Behavior has no objective comparator. The caregiver placebo effect was quantified in orthopedics because force platform gait analysis exists (Conzemius & Evans, 2012). No equivalent standard exists for calmness, reactivity or trainability, so the size of the effect in behavioral diet trials is unknown rather than known to be small.

Placebo response is not a fixed quantity to subtract. The epilepsy literature produced a substantial response in one analysis and none in another using crossover designs (Muñana et al., 2010; Schmidt et al., 2024). Trial design appears to change it, which means it cannot be estimated once and applied generally.

Nobody has run the null-result trials. The commercial incentive runs toward testing whether products work, not whether widely sold ones do nothing. The absence of such trials is a feature of the funding structure rather than of the evidence.

Washout periods are unvalidated. Crossover designs require knowing how long a dietary effect persists after the diet stops. For a hypothesized behavioral effect in dogs, that time course has not been established.

14. Conclusion

The diet–behavior literature has an unusual shape: a mechanism that is well understood, an evidence base that is thin, and an advice landscape that behaves as though the opposite were true. The tryptophan transport story is correct biochemistry and it has been examined in several canine trials, with the largest blinded and placebo-controlled trial — 138 privately owned dogs over eight weeks with a 2.6-fold supplementation dose — finding no significant effect on anxious behavior. The study that everyone quotes instead used 33 dogs for one week per ration, found nothing within its behavioral groups, and produced its headline result only in a pooled analysis conditional on two variables at once. The microbiome has since inherited the same enthusiasm, and the most comprehensive canine study to date found minimal differences in relative abundance, with group membership recoverable only through machine-learning models — while the researchers reviewing the field describe their own evidence as preliminary. None of this means diet is irrelevant to behavior. It means the connection runs mainly through discomfort, structure and reinforcement rather than through neurotransmitter precursors: a dog in gastrointestinal pain behaves differently, a dog fed unpredictably behaves differently, and food remains the most useful training tool available. Those three are supported, cost nothing, and are almost entirely absent from the advice that dominates the subject (much as the supported interventions are elsewhere).

Key Insights (Takeaways)

• The strongest controlled trial available returned a null result. Randomised, double-blinded and placebo-controlled, with 66 control and 72 supplemented dogs over eight weeks at 2.6-fold tryptophan, dietary supplementation had no significant effect on anxious behavior (Bosch et al., 2009). It is the strongest study on the question and among the least quoted outside academic work.

• The study behind "feed less protein" does not support it. DeNapoli et al. (2000) used 33 dogs and one week per ration, found no significant effect within any behavioral group, and produced a lower territorial aggression score only in a pooled analysis and only where high tryptophan coincided with low protein. Twenty-five years later it remains the source of the recommendation.

• Metabolic differences in fearful dogs run both ways. Fearful dogs show altered tryptophan metabolism (Puurunen et al., 2016), and chronic stress alters metabolism — so the profile may be a consequence rather than a cause. Serum concentrations are also not brain concentrations, which is the whole point of the transport mechanism.

• The microbiome evidence is weaker than its coverage. In the most comprehensive canine study to date, differences in relative abundance between behavioral groups were minimal, and only machine-learning and compositional models could predict group membership (Pellowe et al., 2025). The field's own critical review calls the findings not definitive and the methodology unstandardized (Crisante et al., 2025).

• Diet does affect behavior — through discomfort, structure and reinforcement. Pain features heavily in behavior caseloads (Mills et al., 2020), gastrointestinal upset changes how a dog behaves, predictable feeding reduces anticipatory arousal, and food is the most useful reinforcer available. None of these involve manipulating a precursor, and all of them are better supported than the interventions being sold.

References

Bosch, G., Beerda, B., Beynen, A. C., van der Borg, J. A. M., van der Poel, A. F. B., & Hendriks, W. H. (2009). Dietary tryptophan supplementation in privately owned mildly anxious dogs. Applied Animal Behaviour Science, 121(3–4), 197–205. https://doi.org/10.1016/j.applanim.2009.10.003

Bosch, G., Beerda, B., Hendriks, W. H., van der Poel, A. F. B., & Verstegen, M. W. A. (2007). Impact of nutrition on canine behaviour: Current status and possible mechanisms. Nutrition Research Reviews, 20(2), 180–194. https://doi.org/10.1017/S095442240781331X

Conzemius, M. G., & Evans, R. B. (2012). Caregiver placebo effect for dogs with lameness from osteoarthritis. Journal of the American Veterinary Medical Association, 241(10), 1314–1319. https://doi.org/10.2460/javma.241.10.1314

Crisante, A., Newberry, F., Clegg, S. R., Mitchell, G. L., Pike, T. W., Ratcliffe, V., Spain, A., Wilkinson, A., Zulch, H., & Mills, D. S. (2025). A critical review of research concerning the gut microbiome in dogs and its relationship with behaviour. Applied Animal Behaviour Science, 292, 106755. https://doi.org/10.1016/j.applanim.2025.106755

DeNapoli, J. S., Dodman, N. H., Shuster, L., Rand, W. M., & Gross, K. L. (2000). Effect of dietary protein content and tryptophan supplementation on dominance aggression, territorial aggression, and hyperactivity in dogs. Journal of the American Veterinary Medical Association, 217(4), 504–508. https://doi.org/10.2460/javma.2000.217.504

Kirchoff, N. S., Udell, M. A. R., & Sharpton, T. J. (2019). The gut microbiome correlates with conspecific aggression in a small population of rescued dogs (Canis familiaris). PeerJ, 7, e6103. https://doi.org/10.7717/peerj.6103

Mills, D. S., Demontigny-Bédard, I., Gruen, M., Klinck, M. P., McPeake, K. J., Barcelos, A. M., Hewison, L., Van Haevermaet, H., Denenberg, S., Hauser, H., Koch, C., Ballantyne, K., Wilson, C., Mathkari, C. V., Pounder, J., Garcia, E., Darder, P., Fatjó, J., & Levine, E. (2020). Pain and problem behavior in cats and dogs. Animals, 10(2), 318. https://doi.org/10.3390/ani10020318

Mondo, E., Barone, M., Soverini, M., D'Amico, F., Cocchi, M., Petrulli, C., Mattioli, M., Marliani, G., Candela, M., & Accorsi, P. A. (2020). Gut microbiome structure and adrenocortical activity in dogs with aggressive and phobic behavioral disorders. Heliyon, 6(1), e03311. https://doi.org/10.1016/j.heliyon.2020.e03311

Muñana, K. R., Zhang, D., & Patterson, E. E. (2010). Placebo effect in canine epilepsy trials. Journal of Veterinary Internal Medicine, 24(1), 166–170. https://doi.org/10.1111/j.1939-1676.2009.0407.x

Pellowe, S. D., Zhang, A., Bignell, D. R. D., Peña-Castillo, L., & Walsh, C. J. (2025). Gut microbiota composition is related to anxiety and aggression scores in companion dogs. Scientific Reports, 15(1), 24336. https://doi.org/10.1038/s41598-025-06178-4

Puurunen, J., Tiira, K., Lehtonen, M., Hanhineva, K., & Lohi, H. (2016). Non-targeted metabolite profiling reveals changes in oxidative stress, tryptophan and lipid metabolisms in fearful dogs. Behavioral and Brain Functions, 12, 7. https://doi.org/10.1186/s12993-016-0091-2

Schmidt, T., Meyerhoff, N., Meller, S., Twele, F., Charalambous, M., Berk, B. A., Law, T. H., Packer, R. M. A., Zanghi, B., Pan, Y., Fischer, A., & Volk, H. A. (2024). Re-evaluating the placebo response in recent canine dietary epilepsy trials. BMC Veterinary Research, 20(1), 224. https://doi.org/10.1186/s12917-024-04066-z

Templeman, J. R., Davenport, G. M., Cant, J. P., Osborne, V. R., & Shoveller, A. K. (2018). The effect of graded concentrations of dietary tryptophan on canine behavior in response to the approach of a familiar or unfamiliar individual. Canadian Journal of Veterinary Research, 82(4), 294–305. https://pubmed.ncbi.nlm.nih.gov/30363384/